Announcement on Obtaining Drug Registration Certificate for Blonanserin Tablets by its Subsidiary
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Announcement on Obtaining Drug Registration Certificate for Blonanserin Tablets by its Subsidiary
Filed with SSE · · 2 pages · Chinese
Release
Zhejiang CONBA Pharmaceutical Co., Ltd. on 6ix
Earlier from Zhejiang CONBA Pharmaceutical
- Report for Q1 2026
- Announcement on Subsidiary Obtaining Drug Registration Certificate for Telmisartan Amlodipine Tablets (III)
- Announcement on Voluntary Exercise Results of Stock Option Incentive Plan in Q1 2026 and Share Changes
- Indicative Announcement on Restricted Exercise Period of Stock Option Incentive Plan of 2022
- Announcement on Results of Shareholding Reduction by Shareholders
Later from Zhejiang CONBA Pharmaceutical
- Announcement on Resolutions of the 2025 Annual General Meeting
- Announcement on Convening Performance Briefing for 2025 and Q1 2026
- Announcement on the Public Listing and Transfer of 100% Equity Interest in Dongyang Conba
- Announcement on Implementation of Dividend Distribution for 2025
- Announcement on Resolutions of the 18th (Extraordinary) Meeting of the 11th Board of Directors
Follow Zhejiang CONBA Pharmaceutical into a list and get an email when it puts out news.
Follow Zhejiang CONBA Pharmaceutical